ONCY
ONCOLYTICS BIOTECH INC
$0.8000
-2.44%
$95.8M
No data for this timeframe.
Vol
Market Cap$95.8M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (75%)
Inst. Holders1 funds
Inst. Value$730.9K
Insider Activity13B / 0S
Insider Net $$258.8K
SEC Reports10
Press Releases1
Recent Activity
Jun 9, 2026
short_volume
Short Volume: ONCY — 60.7% short (0.8M / 1.3M)
Short: 811,320 | Exempt: 0 | TRF Vol: 1,335,903 | Short Ratio: 60.7% | Off-exchange volume (dark poo
Jun 2, 2026
SEC
Oncolytics Biotech announced the appointment of Stephen Glover to its Board of Directors and the promotion of John McAdo
8-K — Impact 2/10
Jun 1, 2026
SEC
Oncologics Biotech announced initial preclinical data showing pelareorep combined with RAS inhibitors demonstrates great
8-K — Impact 3/10
Jun 1, 2026
Insider
Kelly Jared was granted 755,000 shares
Chief Executive Officer
Jun 1, 2026
Insider
Aromando Andrew was granted 260,000 shares
Chief Business Officer
Jun 1, 2026
Insider
Look Kirk was granted 260,000 shares
Chief Financial Officer
May 22, 2026
SEC
Oncolytics announced translational data from the GOBLET and AWARE-1 trials to be presented at ASCO 2026, showing pelareo
8-K — Impact 3/10
May 22, 2026
Press
Oncolytics Biotech announced translational data from the GOBLET and AWARE-1 trials will be presented at ASCO 2026, showi
Impact 4/10
Price Targets
$5.00
+522.6% upside
Strong Buy
Current $0.8030
Low $2.90
Median $4.19
High $9.87
6 analysts
$2.90
$9.87
Analyst Ratings
1Strong Buy
5Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.07 ▼ -0.7% | $-0.08 — $-0.07 | -7% YoY | 4 |
| Next Q | $-0.08 ▼ -1.7% | $-0.08 — $-0.07 | 46% YoY | 4 |
| Current FY | $-0.34 ▲ +10.0% | $-0.36 — $-0.30 | 20% YoY | 4 |
| Next FY | $-0.34 ▲ +8.5% | $-0.44 — $-0.23 | 0% YoY | 5 |
Latest Reports
NEUTRAL
8-K
2/10
Oncolytics Biotech announced the appointment of Stephen Glover to its Board of Directors and the promotion of John McAdo
Jun 2, 2026
NEUTRAL
8-K
3/10
Oncologics Biotech announced initial preclinical data showing pelareorep combined with RAS inhibitors demonstrates great
Jun 1, 2026
NEUTRAL
Press
4/10
Oncolytics Biotech announced translational data from the GOBLET and AWARE-1 trials will be presented at ASCO 2026, showi
May 22, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MARSHALL WACE, LLP | $730.9K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Kelly Jared | A | $0.00 |
| Jun 1, 2026 | Aromando Andrew | A | $0.00 |
| Jun 1, 2026 | Look Kirk | A | $0.00 |
| Jun 1, 2026 | McAdory John | A | $0.00 |
| Jun 1, 2026 | Hagerman Allison | A | $0.00 |
1 institutional holders with $730.9K total value (859,831 shares) as of 2026-Q1. Top holders: MARSHALL.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MARSHALL WACE, LLP | 859,831 | $730.9K | 100.0% | — |
13 unique insiders with 25 transactions. Net insider value: $258.8K ($258.8K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Kelly Jared | Chief Executive Officer | AWARD | 755,000 | — | — |
| Jun 1, 2026 | Aromando Andrew | Chief Business Officer | AWARD | 260,000 | — | — |
| Jun 1, 2026 | Look Kirk | Chief Financial Officer | AWARD | 260,000 | — | — |
| Jun 1, 2026 | McAdory John Bearden | Chief Operating Officer | AWARD | 145,000 | — | — |
| Jun 1, 2026 | Hagerman Allison | Chief Technology Officer | AWARD | 260,000 | — | — |
| Jun 1, 2026 | Parsons James T. | Director | AWARD | 30,000 | — | — |
| Jun 1, 2026 | Seizinger Bernd R. | Director | AWARD | 30,000 | — | — |
| Jun 1, 2026 | Heineman Thomas Charles | Chief Medical Officer | AWARD | 260,000 | — | — |
| Jun 1, 2026 | Glover Stephen C. | Director | AWARD | 96,000 | — | — |
| Jun 1, 2026 | Holtham Angela | Director | AWARD | 30,000 | — | — |
| Jun 1, 2026 | Andrews Patricia S | Director | AWARD | 30,000 | — | — |
| Jun 1, 2026 | Brown Deborah Margaret | Director | AWARD | 30,000 | — | — |
| Mar 12, 2026 | Kelly Jared | Chief Executive Officer | BUY | 5,050 | $0.9600 | $4.8K |
| Mar 11, 2026 | Parsons James T. | Director | BUY | 10,000 | $1.03 | $10.3K |
| Feb 12, 2026 | Look Kirk | Chief Financial Officer | BUY | 12,000 | $0.8420 | $10.1K |
| Feb 12, 2026 | Pisano Wayne | Director | BUY | 30,000 | $0.8446 | $25.3K |
| Feb 12, 2026 | Kelly Jared | Chief Executive Officer | BUY | 29,500 | $0.8420 | $24.8K |
| Feb 12, 2026 | Heineman Thomas Charles | Chief Medical Officer | BUY | 12,132 | $0.8270 | $10.0K |
| Feb 12, 2026 | Brown Deborah Margaret | Director | BUY | 25,000 | $0.8496 | $21.2K |
| Feb 12, 2026 | Seizinger Bernd R. | Director | BUY | 40,000 | $0.8466 | $33.9K |
| Feb 12, 2026 | Andrews Patricia S | Director | BUY | 35,400 | $0.8557 | $30.3K |
| Feb 12, 2026 | Hagerman Allison | VP, Product Development | BUY | 10,000 | $0.8298 | $8.3K |
| Feb 11, 2026 | Aromando Andrew | Chief Business Officer | BUY | 29,600 | $0.8587 | $25.4K |
| Feb 11, 2026 | Kelly Jared | Chief Executive Officer | BUY | 5,600 | $0.8360 | $4.7K |
| Feb 11, 2026 | Seizinger Bernd R. | Director | BUY | 60,000 | $0.8265 | $49.6K |
10 SEC filing reports analyzed. Sentiment: 4 bullish, 3 bearish, 0 mixed, 3 neutral. Avg impact: 5.1/10.
NEUTRAL
8-K
2/10
Oncolytics Biotech announced the appointment of Stephen Glover to its Board of Directors and the pro
Jun 2, 2026
NEUTRAL
8-K
3/10
Oncologics Biotech announced initial preclinical data showing pelareorep combined with RAS inhibitor
Jun 1, 2026
NEUTRAL
8-K
3/10
Oncolytics announced translational data from the GOBLET and AWARE-1 trials to be presented at ASCO 2
May 22, 2026
BULLISH
8-K
7/10
Oncolytics Biotech announced alignment with the FDA on a randomized controlled pivotal trial design
Apr 27, 2026
BEARISH
424B5
6/10
Oncolytics Biotech is conducting an at-the-market offering of up to $75 million in common stock thro
Apr 6, 2026
BULLISH
8-K
6/10
Oncolytics Biotech announced a scheduled Type C meeting with the FDA on April 16, 2026, to discuss a
Apr 6, 2026
BEARISH
EFFECT
6/10
Oncolytics Biotech's S-3 shelf registration has become effective, allowing the company to issue up t
Apr 6, 2026
BEARISH
S-3
6/10
Oncolytics Biotech filed a shelf registration (S-3) to offer up to $250 million in securities, inclu
Apr 1, 2026
BULLISH
CLUSTER
5/10
Two corporate insiders at Oncolytics Biotech purchased shares in the open market within the past wee
Mar 13, 2026
BULLISH
8-K
7/10
Oncolytics Biotech announced it will prioritize registrational studies in squamous cell anal cancer
Feb 24, 2026
Current analyst consensus: Buy (75% buy). Based on 8 analysts: 1 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.00 mean target
+522.6% upside
Strong Buy (1.83)
$2.90 Low
$9.87 High
| Metric | Value |
|---|---|
| Current Price | $0.8030 |
| Target Low | $2.90 |
| Target Mean | $5.00 |
| Target Median | $4.19 |
| Target High | $9.87 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.83) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.07 | $-0.08 | $-0.07 | -7.1% | -0.7% | 2↑ 1↓ | $0.0B | 0.0% | 4 |
| Next Q 2026-09-30 |
$-0.08 | $-0.08 | $-0.07 | 45.9% | -1.7% | 2↑ 1↓ | $0.0B | 0.0% | 4 |
| Current FY 2026-12-31 |
$-0.34 | $-0.36 | $-0.30 | 19.5% | +10.0% | 1↑ 2↓ | $0.0B | 0.0% | 4 |
| Next FY 2027-12-31 |
$-0.34 | $-0.44 | $-0.23 | 0.3% | +8.5% | 2↑ 1↓ | $0.0B | 0.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.075 | |
| 7d ago | $-0.073 | -0.002 |
| 30d ago | $-0.074 | -0.001 |
| 60d ago | $-0.075 | |
| 90d ago | $-0.069 | -0.006 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| May 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| Apr 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| Mar 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| Feb 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| Jan 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
Recent Reddit Threads
Jun 9, 2026
short_volume
Short Volume: ONCY — 60.7% short (0.8M / 1.3M)
Short: 811,320 | Exempt: 0 | TRF Vol: 1,335,903 | Short Ratio: 60.7% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: ONCY — 67.0% short (0.4M / 0.6M)
Short: 427,270 | Exempt: 1,671 | TRF Vol: 638,059 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
other
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
Oncolytics Biotech announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer.
May 22, 2026
fda
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor g
May 19, 2026
short_volume
Short Volume: ONCY — 67.8% short (0.4M / 0.5M)
Short: 366,538 | Exempt: 9,599 | TRF Vol: 540,780 | Short Ratio: 67.8% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: ONCY — 62.6% short (0.4M / 0.6M)
Short: 350,657 | Exempt: 2,000 | TRF Vol: 560,105 | Short Ratio: 62.6% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
short_volume
Short Volume: ONCY — 59.3% short (0.6M / 1.0M)
Short: 567,495 | Exempt: 42,526 | TRF Vol: 956,546 | Short Ratio: 59.3% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
other
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
Oncolytics Biotech announced Type C meeting with the FDA aligning on the design of clinical study to support approval of pelareorep in patients with S
Apr 27, 2026
short_volume
Short Volume: ONCY — 63.8% short (2.0M / 3.2M)
Short: 2,025,897 | Exempt: 21,485 | TRF Vol: 3,177,252 | Short Ratio: 63.8% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
short_volume
Short Volume: ONCY — 58.9% short (0.5M / 0.8M)
Short: 462,983 | Exempt: 100 | TRF Vol: 785,922 | Short Ratio: 58.9% | Off-exchange volume (dark pool + OTC)
Apr 13, 2026
short_volume
Short Volume: ONCY — 59.5% short (0.5M / 0.9M)
Short: 510,110 | Exempt: 49,117 | TRF Vol: 857,025 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
Apr 10, 2026
short_volume
Short Volume: ONCY — 58.7% short (0.8M / 1.4M)
Short: 813,724 | Exempt: 26,344 | TRF Vol: 1,386,828 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
short_volume
Short Volume: ONCY — 62.2% short (0.4M / 0.6M)
Short: 350,749 | Exempt: 21,264 | TRF Vol: 563,775 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
Apr 7, 2026
short_volume
Short Volume: ONCY — 70.9% short (0.4M / 0.6M)
Short: 415,211 | Exempt: 15,533 | TRF Vol: 585,893 | Short Ratio: 70.9% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
other
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
<p align="justify">SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech<sup>®</sup> Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”),